If you’re waiting on a Johnson and Johnson settlement check for a talcum powder cancer claim, there is nothing to wait for yet: no court-approved global settlement fund exists. Johnson & Johnson’s third and final attempt to resolve the litigation through bankruptcy was rejected on March 31, 2025, and the company withdrew its roughly $8–9 billion settlement offer. Claims are now being resolved one at a time through individual settlements and jury trials, and more than 67,000 cases remain pending.
Why There Is No Global Settlement Fund
Between 2021 and 2024, J&J tried three times to move its talc liabilities into a subsidiary, put the subsidiary into Chapter 11, and use the bankruptcy to create a trust that would pay claimants a set amount and end the litigation. The maneuver is known as the Texas Two-Step.
The first two attempts, filed by a subsidiary called LTL Management in October 2021 and April 2023, were both dismissed. The Third Circuit ruled in January 2023 that LTL was not in genuine financial distress because J&J had committed up to $61.5 billion to backstop it. A second dismissal followed in July 2023.
For the third attempt, J&J created Red River Talc LLC, which filed a prepackaged Chapter 11 plan in the Southern District of Texas in September 2024. On March 31, 2025, U.S. Bankruptcy Judge Christopher Lopez dismissed the case and denied confirmation of the plan. He identified three problems:
- The voting process was flawed. Plaintiffs’ law firms had cast tens of thousands of ballots without direct client authorization, and one firm switched roughly 11,000 client votes from “reject” to “accept” for an amended plan, giving those clients under two days to opt out. The initial vote was about 70%, short of the 75% required, and the switch pushed it over.
- The plan contained nonconsensual releases shielding more than 700 non-debtor entities, including retailers and Kenvue, the consumer-health company J&J spun off in 2023. Citing the Supreme Court’s June 2024 decision in Harrington v. Purdue Pharma, Judge Lopez ruled those releases were not authorized by the bankruptcy code.
- The case lacked good faith. There was no operating business to save and no employees whose jobs were at stake, only a vehicle to cap tort exposure.
J&J announced it would not appeal and withdrew the settlement offer. That is why there is no settlement trust, no claim form portal, and no check.
How Talc Cases Are Being Resolved Now
With the bankruptcy path closed, the litigation is proceeding through the normal court system. About 67,600 cases are consolidated in a federal multidistrict litigation (MDL 2738) before U.S. District Judge Michael A. Shipp in New Jersey, and individual state-court cases are moving forward around the country.
In August 2025, Judge Shipp allowed plaintiffs to add Kenvue, Holdco, and Janssen as defendants in the MDL’s master complaint. A mediator, Fouad Kurdi of Resolutions LLC, was appointed in July 2025, and the parties were scheduled to meet in April 2026 to discuss potential resolutions. J&J has publicly stated it does not currently intend to offer settlements and plans to defend remaining claims at trial.
The first federal bellwether trial, Carter Judkins v. Johnson & Johnson, has been designated but does not yet have a firm trial date. In January 2026, Special Master Judge Freda Wolfson recommended allowing plaintiffs’ experts to testify about the link between talcum powder and ovarian cancer.
Jury trials since the bankruptcy collapse have produced a mix of large verdicts and reductions on appeal. A Baltimore jury awarded $1.5 billion in December 2025 (including $59.84 million in compensatory damages) to Cherie Craft, a mesothelioma patient. A Los Angeles jury awarded $966 million to the family of Mae Moore in October 2025, but a California judge threw out the $950 million punitive portion in March 2026, leaving $16 million. Other results include $42 million in Boston (July 2025), $40 million in a California bellwether (December 2025), $20 million in Fort Lauderdale (November 2025), and $250,000 in Philadelphia (February 2026). J&J appeals virtually every adverse verdict, and punitive damages face constitutional limits on how far they can exceed compensatory awards.
What Individual Claimants Are Actually Receiving
Because no global settlement trust exists, there is no standardized payment schedule and no fixed per-claimant amount. Every case is being resolved on its own facts, either by individual settlement or by verdict.
Legal industry estimates put the average individual talc settlement at roughly $500,000, but actual amounts vary widely with the type and severity of cancer, medical expenses, lost earnings, duration of product use, and the strength of the evidence. Mesothelioma claims generally command higher awards than ovarian cancer claims because the link between asbestos exposure and mesothelioma is better established. Final settlement amounts are typically confidential.
When an individual case does settle, claimants generally receive payment within one to two months after the agreement is finalized. In group settlements, payouts may take longer because plaintiffs are compensated in waves, with early filers paid first.
The $700 Million State Settlement Is Not for Individuals
In June 2024, J&J agreed to pay $700 million to settle an investigation by 42 state attorneys general and Washington, D.C., which alleged the company had deceptively marketed talc-based Baby Powder and Shower to Shower as safe despite internal knowledge, dating to the 1950s, that the products were sometimes contaminated with asbestos. The agreement also permanently bans J&J from manufacturing, selling, or distributing talc-based baby or body powder in the United States. New Jersey alone is set to receive over $30.2 million.
That money goes to the states, not to individual cancer patients. It has no connection to the personal-injury lawsuits and does not produce checks for claimants.
The Imerys Talc Trust Is a Separate Case
Imerys Talc America, a former talc supplier to J&J, has proposed an $862 million trust fund through its own bankruptcy to resolve thousands of claims. As part of that process, Imerys reached a settlement with J&J, approved by a Delaware bankruptcy court in October 2024, that brought in about $505 million. A confirmation hearing on the final trust plan concluded in February 2026, but the court had not issued a decision as of mid-2026, and no payouts from the Imerys trust have begun.
What to Expect Going Forward
Johnson & Johnson maintains its talc products are safe, do not contain asbestos, and do not cause cancer, and points to winning the majority of ovarian cancer cases that have gone to trial. The company discontinued talc-based Baby Powder in the U.S. in 2020 and ended global sales of the talc formula in 2023, replacing it with a cornstarch-based product.
With no global settlement on the horizon, the litigation is expected to continue for years. Some industry analysts estimate J&J may ultimately need to spend as much as $11 billion to resolve all pending lawsuits. If you have a filed claim, any recovery will come through your own attorney and your own case, not from a central settlement fund. If you do not have counsel, the practical next step is to speak with a lawyer handling talc cases in the MDL or in your state.